← Back to Clinical Trials
Recruiting Phase 3 NCT06775431

NCT06775431 Comparing Prophylactic Intravenous Pethidine and Intrathecal Pethidine in Preventing Post Spinal Shivering in Caesarean Section

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06775431
Status Recruiting
Phase Phase 3
Sponsor Alexandria University
Condition Pregnant Women
Study Type INTERVENTIONAL
Enrollment 86 participants
Start Date 2024-12-10
Primary Completion 2025-02

Eligibility & Interventions

Sex Female only
Min Age 20 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
Pethidine Hydrochloride 50 Mg/mL Solution for InjectionPethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 86 participants in total. It began in 2024-12-10 with a primary completion date of 2025-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to assess the effect of IV pethidine and intrathecal pethidine on the incidence, onset, duration, and intensity of shivering in females undergoing caesarean section. The main question it aims to answer is: which route is more efficacious in preventing shivering. Researchers will compare IV pethidine and intrathecal pethidine to see their effects on post spinal shivering, their effects on hemodynamic stability, nausea, vomiting, and sedation.

Eligibility Criteria

Inclusion Criteria: \- Exclusion Criteria: 1. contraindications to spinal 2. uncontrolled hypertension, diabetes mellitus, hepatic, pulmonary diseases, and thyroid disease 3. obesity (BMI \>35) 4. drug allergy 5. temperature below 36 degrees celcius or above 37.5 degrees celcius

Contact & Investigator

Central Contact

Mai A El-Sayed, Lecturer of Anesthesia

✉ m_mohamed165@alexmed.edu.eg

📞 00201287459922

Frequently Asked Questions

Who can join the NCT06775431 clinical trial?

This trial is open to female participants only, aged 20 Years or older, up to 40 Years, studying Pregnant Women. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06775431 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 86 participants.

Is NCT06775431 currently recruiting?

Yes, NCT06775431 is actively recruiting participants. Contact the research team at m_mohamed165@alexmed.edu.eg for enrollment information.

Where is the NCT06775431 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT06775431 clinical trial?

NCT06775431 is sponsored by Alexandria University. The trial plans to enroll 86 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology